Extensive experience in genome engineering

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008, and provides life science researchers with targeted integration products based on Meganuclease-driven Homologous Recombination.

Since its inception in 1999, Cellectis has been a pioneer in the field of genome engineering. Our parent company has extensive experience on meganucleases and meganuclease engineering and expertise in biological repair mechanisms such as Homologous Recombination.

Meganucleases are highly specific DNA endonucleases that enable precise modifications of genomic DNA, with applications in the research, bioproduction, agrobiotechnology, and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 granted or pending patents.  Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris, and has secured over €70 million in funding since inception in 1999.